查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2137159

粒細胞和巨噬細胞集落刺激因子市場：全球市場預測，2026-2032年

Granulocyte Macrophage Colony Stimulating Factor Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

粒細胞-巨噬細胞集落刺激因子 (GM-CSF) 市場預計到 2032 年將成長至 51.5 億美元，複合年成長率為 10.48%。

主要市場統計數據
基準年 2025 25.6億美元
預計年份：2026年 28億美元
預測年份 2032 51.5億美元
複合年成長率 (%) 10.48%

粒細胞-巨噬細胞集落刺激因子（GM-CSF）是一種造血生長因子，可促進粒細胞、巨噬細胞及相關免疫細胞的發育和功能活性。其臨床意義涵蓋支持治療、免疫調節以及腫瘤、感染疾病、發炎性疾病和組織修復等領域的臨床實驗。此領域的發展受到製劑形式、給藥途徑、監管狀態、安全性監測以及GM-CSF應用生物學背景等因素的影響。

粒細胞-巨噬細胞集落刺激因子（GM-CSF）的開發和應用發生了變革性變化

目前的研究重點正從單純的血球修復轉向更具選擇性地將GM-CSF用作免疫調節療法。研究人員正在探索劑量、給藥時間、給藥途徑、聯合療法以及患者選擇等策略，以平衡免疫活化和發炎風險。研發重點還包括提高耐受性、開發更清晰的生物標記策略，以及建立證據來區分支持性治療的益處和更廣泛的緩解疾病作用。

人工智慧對GM-CSF調查的影響

人工智慧正透過病患分層、免疫細胞譜分析、臨床試驗受試者招募、藥物安全性監測以及高維度生物資料解讀等方式，協助GM-CSF的研究。機器學習技術有助於識別臨床和真實世界資料集中的反應模式和安全性訊號，而計算模型則可輔助確定製劑和劑量。為了使這些應用能夠指南常規治療決策，檢驗的資料集、透明的演算法、臨床監督和前瞻性檢驗仍然至關重要。

區域層面對GM-CSF現狀的見解

北美擁有堅實的生物製藥臨床研究、專科護理和監管基礎設施基礎。歐洲則著重於實證標準、藥物安全監測以及國家醫療體系間的協調評估。亞太地區的特點是生物醫學能力不斷提升，但監管路徑和醫療服務可近性也存在顯著差異。拉丁美洲受到公共部門採購、本地生產能力和先進療法可及性差異的影響。中東的腫瘤和免疫專科服務正在發展，而非洲的優先事項包括可負擔性、供應連續性、診斷能力以及融入更廣泛的醫療體系。

區域洞察：東協、金磚國家、歐盟、七國集團、海灣合作理事會、北約

東南亞國協呈現多元化的環境，在監管協調、專家能力和生物製藥取得方面有顯著差異。金磚國家成員國擁有龐大且多元化的患者群體，研發和生產能力也不斷提升，但在報銷系統和臨床基礎設施方面卻存在差異。歐盟受益於通用的科學和監管機制，但成員國在衛生技術評估方面仍有差異。七國集團成員國普遍擁有成熟的研究生態系及完善的藥物安全監測體系。海灣合作理事會成員國正在加強其三級醫療保健體系和區域採購體系，而北約成員國總體上擁有許多先進的生物醫學體系，但在醫療保健政策和治療可及性方面仍然存在差距。

針對15個重點市場的國家特定洞察

美國和加拿大擁有完善的癌症治療和免疫學基礎設施，而英國、法國、德國、義大利和西班牙則在成熟的歐洲實證醫學和醫療保健報銷框架下運作。日本和韓國擁有先進的生技藥品研發能力和高度發展的臨床體系。中國和印度正在擴大其國內的研究、生產和專科醫療體系，但不同地區的醫療服務可近性差異顯著。澳洲擁有強大的臨床管治和研究網路。巴西和墨西哥的特點是公共採購、私人醫療以及區域間醫療服務可近性差異。俄羅斯的情況反映了其國內醫療優先事項、法規環境和專科治療可近性的差異。在這些國家，該療法的引入受到實證醫學品質、適應症指南、醫保報銷機制、供應可靠性和臨床醫生水平的影響。

GM-CSF產業領導者的實際優先事項

行業領導者應優先考慮每項適應症的證據、明確的患者選擇策略以及透明的獲益-風險溝通。研發項目應納入具有臨床意義的終點指標、免疫和發炎生物標記以及長期安全性追蹤。准入計畫必須涵蓋生產彈性、冷鏈要求、可負擔性以及各國特定的報銷途徑。與醫院和學術機構的合作可以改善臨床試驗的進行和真實世界數據（REW）的收集。同時，負責任地使用人工智慧（AI）需要檢驗的資料、可解釋性、隱私保護以及人體臨床管治。

調查方法執行摘要

本執行摘要對粒細胞-巨噬細胞集落刺激因子（GM-CSF）的治療現狀進行了結構化回顧，重點關注其作用機制、臨床應用、發展趨勢、監管考慮、醫療系統現狀以及區域可及性因素。內容按指定區域、經濟和政治集團以及國家/地區進行分類。結論僅限於已確立或廣泛記錄的定性模式，不包含市場規模估算或預測、市場佔有率、預測或針對特定公司的評估。解讀本概要時，應結合最新的臨床試驗記錄、監管文件、治療指南、同行評審文獻以及國家/地區的醫保報銷資訊。

結論：建構基於證據的GM-CSF策略

GM-CSF 仍然是一種具有重要臨床意義的生物製藥，但其價值取決於適應症、治療目標、患者特徵以及發炎風險管理等因素。該領域的下一階段將以更精準的用藥、更強力的生物標記證據、更完善的安全監測以及在不同醫療體系中公平的可及性為特徵。那些能夠將科學檢驗與監管準備、營運韌性和負責任的數據利用相結合的領導者，將更有能力支持臨床的持續進展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：粒細胞和巨噬細胞集落刺激因子市場：依產品分類

  • 生物相似藥
    • 已通過核准的
    • 開發中
  • 重組
    • 已通過核准的
    • 開發中

第8章：粒細胞-巨噬細胞集落刺激因子市場：依途徑分類

  • 靜脈
  • 皮下

第9章：粒細胞和巨噬細胞集落刺激因子市場：依劑型分類

  • 液體
    • 已通過核准的
    • 開發中
  • 凍乾粉
    • 已通過核准的
    • 開發中

第10章：粒細胞和巨噬細胞集落刺激因子市場：依應用分類

  • 急性骨髓性白血病
    • 已通過核准的
    • 開發中
  • 化療引起的嗜中性白血球低下症
    • 已通過核准的
    • 開發中
  • 慢性骨髓性白血病
    • 已通過核准的
    • 開發中

第11章：粒細胞和巨噬細胞集落刺激因子市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 研究機構
  • 專科診所

第12章：粒細胞和巨噬細胞集落刺激因子市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：粒細胞和巨噬細胞集落刺激因子市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：粒細胞和巨噬細胞集落刺激因子市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：粒細胞和巨噬細胞集落刺激因子市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Chinook Therapeutics
  • Ferring Pharmaceuticals SA
  • Humanigen, Inc.
  • Landos Biopharma, Inc.
  • Nobelpharma Co., Ltd.
  • Partner Therapeutics, Inc.
  • Samyang Biopharm Co., Ltd.
  • Savara Inc.
  • Teva Pharmaceuticals Europe BV
  • Thermo Fisher Scientific Inc.
  • Zenyaku Kogyo Co., Ltd.

第18章 主要專家

Product Code: MRR-961F26FD7FCD

The Granulocyte Macrophage Colony Stimulating Factor Market is projected to grow by USD 5.15 billion at a CAGR of 10.48% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.56 billion
Estimated Year [2026] USD 2.80 billion
Forecast Year [2032] USD 5.15 billion
CAGR (%) 10.48%

Granulocyte macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that promotes the development and functional activity of granulocytes, macrophages, and related immune cells. Its clinical relevance spans supportive care, immune modulation, and investigational approaches in oncology, infectious disease, inflammatory disorders, and tissue repair. The field is shaped by product formulation, route of administration, regulatory status, safety monitoring, and the biological context in which GM-CSF is used.

Transformative Shifts in GM-CSF Development and Use

The landscape is shifting from a narrow focus on blood-cell recovery toward more selective use of GM-CSF as an immune-modulating therapy. Research is increasingly examining dose, timing, delivery route, combination treatment, and patient selection to balance immune activation with inflammatory risk. Development priorities also include improved tolerability, clearer biomarker strategies, and evidence that distinguishes supportive-care benefits from broader disease-modifying effects.

How Artificial Intelligence Is Influencing GM-CSF Research

Artificial intelligence is contributing to GM-CSF research through patient stratification, analysis of immune-cell profiles, trial recruitment, pharmacovigilance, and interpretation of high-dimensional biological data. Machine-learning methods can help identify response patterns and safety signals across clinical and real-world datasets, while computational modeling may support formulation and dosing decisions. These applications remain dependent on validated datasets, transparent algorithms, clinical oversight, and prospective confirmation before they can guide routine treatment decisions.

Regional Insights Across the GM-CSF Landscape

North America has a strong base of clinical research, specialized care, and regulatory infrastructure for biologic therapies. Europe emphasizes evidence standards, pharmacovigilance, and coordinated assessment across national health systems. Asia-Pacific combines expanding biomedical capacity with substantial variation in regulatory pathways and healthcare access. Latin America is influenced by public-sector procurement, local manufacturing capabilities, and uneven access to advanced therapies. The Middle East is developing specialized oncology and immunology services, while Africa's priorities include affordability, supply continuity, diagnostic capacity, and integration into broader health-system needs.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN countries present a diverse environment in which regulatory harmonization, specialist capacity, and access to biologics differ considerably. BRICS members combine large and varied patient populations with growing research and manufacturing capabilities, but face differences in reimbursement and clinical infrastructure. The European Union benefits from shared scientific and regulatory mechanisms alongside national differences in health-technology assessment. G7 members generally have mature research ecosystems and established pharmacovigilance systems. GCC states are strengthening tertiary-care capacity and regional procurement, while NATO members collectively include many advanced biomedical systems but remain heterogeneous in healthcare policy and treatment access.

Country Insights for Fifteen Priority Markets

The United States and Canada have extensive oncology and immunology infrastructure, while the United Kingdom, France, Germany, Italy, and Spain operate within mature European evidence and reimbursement frameworks. Japan and South Korea combine advanced biologics capabilities with highly developed clinical systems. China and India are expanding domestic research, manufacturing, and specialist-care capacity, with important regional variation in access. Australia has strong clinical governance and research networks. Brazil and Mexico are shaped by public procurement, private-sector care, and unequal geographic access. Russia's environment reflects domestic healthcare priorities, regulatory conditions, and variable availability of specialized treatment. Across these countries, adoption is influenced by evidence quality, indication-specific guidance, reimbursement, supply reliability, and clinician familiarity.

Actionable Priorities for GM-CSF Industry Leaders

Industry leaders should prioritize indication-specific evidence, well-defined patient-selection strategies, and transparent benefit-risk communication. Development programs should incorporate clinically meaningful endpoints, immune and inflammatory biomarkers, and long-term safety follow-up. Access planning should address manufacturing resilience, cold-chain requirements, affordability, and country-specific reimbursement pathways. Partnerships with hospitals and academic centers can improve trial execution and real-world evidence, while responsible use of artificial intelligence requires validated data, explainability, privacy safeguards, and human clinical governance.

Research Methodology for the Executive Summary

This executive summary uses a structured review of the GM-CSF therapeutic landscape, focusing on mechanism, clinical applications, development trends, regulatory considerations, healthcare-system context, and regional access factors. Insights are organized across the specified regions, economic and political groups, and countries. Claims are limited to established or broadly documented qualitative patterns; no market estimates, market shares, forecasts, or company-specific assessments are included. Interpretation should be supplemented with current clinical-trial records, regulatory documents, treatment guidelines, peer-reviewed literature, and country-level reimbursement information.

Conclusion: Building Evidence-Led GM-CSF Strategies

GM-CSF remains a clinically relevant but context-dependent biologic whose value depends on the indication, treatment objective, patient profile, and management of inflammatory risk. The next phase of the field will be defined by more precise use, stronger biomarker evidence, robust safety monitoring, and equitable delivery across diverse health systems. Leaders that connect scientific validation with regulatory readiness, operational resilience, and responsible data use will be better positioned to support durable clinical progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Granulocyte Macrophage Colony Stimulating Factor Market, by Product

  • 7.1. Introduction
  • 7.2. Biosimilar
    • 7.2.1. Approved
    • 7.2.2. In Development
  • 7.3. Recombinant
    • 7.3.1. Approved
    • 7.3.2. In Development

8. Granulocyte Macrophage Colony Stimulating Factor Market, by Route

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Subcutaneous

9. Granulocyte Macrophage Colony Stimulating Factor Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Liquid Solution
    • 9.2.1. Approved
    • 9.2.2. In Development
  • 9.3. Lyophilized Powder
    • 9.3.1. Approved
    • 9.3.2. In Development

10. Granulocyte Macrophage Colony Stimulating Factor Market, by Application

  • 10.1. Introduction
  • 10.2. Acute Myeloid Leukemia
    • 10.2.1. Approved
    • 10.2.2. In Development
  • 10.3. Chemotherapy Induced Neutropenia
    • 10.3.1. Approved
    • 10.3.2. In Development
  • 10.4. Chronic Myelogenous Leukemia
    • 10.4.1. Approved
    • 10.4.2. In Development

11. Granulocyte Macrophage Colony Stimulating Factor Market, by End User

  • 11.1. Introduction
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Research Institutions
  • 11.5. Specialty Clinics

12. Granulocyte Macrophage Colony Stimulating Factor Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Granulocyte Macrophage Colony Stimulating Factor Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Granulocyte Macrophage Colony Stimulating Factor Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Granulocyte Macrophage Colony Stimulating Factor Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Chinook Therapeutics
  • 17.2. Ferring Pharmaceuticals S.A.
  • 17.3. Humanigen, Inc.
  • 17.4. Landos Biopharma, Inc.
  • 17.5. Nobelpharma Co., Ltd.
  • 17.6. Partner Therapeutics, Inc.
  • 17.7. Samyang Biopharm Co., Ltd.
  • 17.8. Savara Inc.
  • 17.9. Teva Pharmaceuticals Europe B.V.
  • 17.10. Thermo Fisher Scientific Inc.
  • 17.11. Zenyaku Kogyo Co., Ltd.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Granulocyte Macrophage Colony Stimulating Factor Market, Years Considered for the Study
  • FIGURE 2. Global Granulocyte Macrophage Colony Stimulating Factor Market, Research Design
  • FIGURE 3. Global Granulocyte Macrophage Colony Stimulating Factor Market, Research Framework
  • FIGURE 4. Global Granulocyte Macrophage Colony Stimulating Factor Market, Data Triangulation
  • FIGURE 5. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2025 vs 2032 (%)
  • FIGURE 7. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2025 vs 2032 (%)
  • FIGURE 9. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 11. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Granulocyte Macrophage Colony Stimulating Factor Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Granulocyte Macrophage Colony Stimulating Factor Market Segmentation & Coverage
  • TABLE 2. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 4. Global Biosimilar Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Biosimilar Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Biosimilar Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global In Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global In Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global In Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global In Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global In Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global In Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 23. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 30. Global Liquid Solution Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Liquid Solution Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Liquid Solution Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global In Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global In Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global In Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global In Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global In Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global In Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 49. Global Acute Myeloid Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Acute Myeloid Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Acute Myeloid Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global In Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global In Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global In Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Chemotherapy Induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Chemotherapy Induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Chemotherapy Induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global In Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global In Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global In Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Chronic Myelogenous Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Chronic Myelogenous Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Chronic Myelogenous Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global In Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global In Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global In Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 77. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Research Institutions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Research Institutions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Research Institutions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 90. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 99. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 102. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 103. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 104. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 105. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 106. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 107. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 108. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 109. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 113. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 114. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 116. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 117. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 118. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 119. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 120. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 121. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 122. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 123. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 124. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 125. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 126. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 127. North America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 128. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 129. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 130. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 131. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 132. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 133. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 134. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 135. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 136. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 137. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 138. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 139. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 140. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 141. Latin America Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 142. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 143. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 144. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 145. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 146. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 147. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 148. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 149. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 150. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 151. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 152. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 153. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 154. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 155. Europe Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 156. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 157. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 158. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 159. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 160. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 161. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 162. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 163. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 164. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 165. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 166. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 167. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 168. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 169. Middle East Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 171. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 172. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 173. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 174. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 175. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 176. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 177. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 178. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 179. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 180. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 181. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 182. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 183. Africa Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 184. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 185. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 186. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 187. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 188. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 189. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 190. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 191. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 192. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 193. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 194. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 195. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 196. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 197. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 198. ASEAN Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 199. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 200. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 201. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 202. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 203. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 204. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 205. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 206. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 207. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 208. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 209. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 210. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 211. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 212. GCC Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 213. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 214. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 215. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 216. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 217. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 218. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 219. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 220. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 221. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 222. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 223. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 224. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 225. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 226. European Union Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 227. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 228. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 229. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 230. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 231. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 232. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 233. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 234. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 235. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 236. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 237. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 238. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 239. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 240. BRICS Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 241. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 242. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 243. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 244. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 245. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 246. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 247. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 248. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 249. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 250. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 251. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 252. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 253. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 254. G7 Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 255. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 256. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 257. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 258. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 259. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 260. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 261. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 262. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 263. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 264. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 265. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 266. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 267. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 268. NATO Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 269. Global Granulocyte Macrophage Colony Stimulating Factor Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 270. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 271. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 272. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 273. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 274. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 275. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 276. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 277. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 278. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 279. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 280. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 281. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chronic Myelogenous Leukemia, 2017-2032 (USD Million)
  • TABLE 282. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 283. United States Granulocyte Macrophage Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 284. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 285. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 286. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 287. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Recombinant, 2017-2032 (USD Million)
  • TABLE 288. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Route, 2017-2032 (USD Million)
  • TABLE 289. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 290. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Liquid Solution, 2017-2032 (USD Million)
  • TABLE 291. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 292. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 293. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Acute Myeloid Leukemia, 2017-2032 (USD Million)
  • TABLE 294. Canada Granulocyte Macrophage Colony Stimulating Factor Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 295. Canada Granulocyte Macrophage Colony Stimulating Factor Marke